title: Non-prescription syringe sales in California: a qualitative examination of practices among 12 local health jurisdictions.
abstract: Legislation permitting non-prescription syringe sales (NPSS) was passed in 2004 in California as a structural intervention designed to expand access to syringes for injection drug users. As of December 2009, 19 of California's 61 local health jurisdictions (LHJs) have approved policies to authorize pharmacies to sell non-prescription syringes. The legislation faces termination in 2010 if current evaluation efforts fail to demonstrate outcomes defined in the legislation. Using qualitative methods, we examined the systems and procedures associated with implementation; identified facilitators and barriers to implementation among 12 LHJs, and documented the role of public health in initiating and sustaining local programs. We identified consistent activities that led to policy implementation among LHJs and discovered several barriers that were associated with failure to implement local programs. Factors leading to NPSS were public health leadership; an inclusive planning process, marketing the program as a public health initiative; learning from others' efforts, successes, and failures; and identifying acceptable syringe disposal options in advance of program implementation. Health departments that were confronted with political and moral arguments lost momentum and ultimately assigned a lower priority to the initiative citing the loss of powerful public health advocates or a lack of human resources. Additional barriers were law enforcement, elected officials, and pharmacy opposition, and failure to resolve syringe disposal options to the satisfaction of important stakeholders. The lessons learned in this study should provide useful guidance for the remaining LHJs in California without NPSS programs.
authors.affiliation: Policy and Evaluation Research, Public Health Foundation Enterprises, Inc., c/o 3311 Florida Street, Oakland, CA 94602, USA. vjkrose@gmail.com
authors.forename: Valerie J
authors.initials: VJ
authors.lastname: Rose
authors.forename: Glenn
authors.initials: G
authors.lastname: Backes
authors.forename: Alexis
authors.initials: A
authors.lastname: Martinez
authors.forename: Willi
authors.initials: W
authors.lastname: McFarland
mesh_terms: D002140:California; D003157:Community Pharmacy Services / Q000331:legislation & jurisprudence / Q000458:organization & administration*; D015658:HIV Infections / Q000517:prevention & control; D006526:Hepatitis C / Q000517:prevention & control; D035846:Law Enforcement; D009111:Local Government; D008389:Marketing of Health Services / Q000458:organization & administration; D018671:Needle-Exchange Programs / Q000331:legislation & jurisprudence / Q000458:organization & administration*; D011635:Public Health Administration; D015819:Substance Abuse, Intravenous
references.citation: Public Health Rep. 1998 Jun;113 Suppl 1:75-80
references.pmid: 9722812
references.citation: J Urban Health. 2003 Sep;80(3):465-81
references.pmid: 12930884
references.citation: J Am Pharm Assoc (Wash). 2002 Nov-Dec;42(6 Suppl 2):S13-8
references.pmid: 12489604
references.citation: J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Sep 1;10(1):82-9
references.pmid: 7648290
references.citation: AIDS Read. 2002 Dec;12(12):527-35
references.pmid: 12518719
references.citation: Health Matrix Clevel. 2001 Winter;11(1):5-64
references.pmid: 11345676
references.citation: MMWR Recomm Rep. 1998 Oct 16;47(RR-19):1-39
references.pmid: 9790221
references.citation: J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18 Suppl 1:S133-8
references.pmid: 9663636
references.citation: J Acquir Immune Defic Syndr. 2001 Nov 1;28(3):264-9
references.pmid: 11694834
references.citation: J Urban Health. 2004 Mar;81(1):118-21
references.pmid: 15047790
references.citation: MMWR Morb Mortal Wkly Rep. 2007 Nov 9;56(44):1164-7
references.pmid: 17989646
references.citation: J Acquir Immune Defic Syndr. 2001 Jun 1;27(2):183-92
references.pmid: 11404541
references.citation: J Urban Health. 2005 Mar;82(1 Suppl 1):i51-61
references.pmid: 15738320
references.citation: J Acquir Immune Defic Syndr. 2003 Jun 1;33(2):199-205
references.pmid: 12794555
references.citation: J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Sep 1;10(1):73-81
references.pmid: 7648288
references.citation: Am J Public Health. 2008 Feb;98(2):278-83
references.pmid: 17538068
references.citation: J Am Pharm Assoc (Wash). 2002 Nov-Dec;42(6 Suppl 2):S77-82
references.pmid: 12489621
references.citation: J Urban Health. 2007 Jan;84(1):116-25
references.pmid: 17151941
references.citation: AIDS. 2000 Jun;14 Suppl 1:S52-6
references.pmid: 10981475
references.citation: Hepatology. 2001 Jul;34(1):180-7
references.pmid: 11431749
references.citation: J Urban Health. 2004 Dec;81(4):661-70
references.pmid: 15466847
references.citation: J Urban Health. 2003 Jun;80(2):302-20
references.pmid: 12791806
references.citation: Public Health Rep. 1998 Jun;113 Suppl 1:81-9
references.pmid: 9722813
references.citation: J Acquir Immune Defic Syndr. 2002 Oct 1;31(2):237-42
references.pmid: 12394803
references.citation: Subst Use Misuse. 1998 Apr;33(5):1147-71
references.pmid: 9596381
references.citation: J Urban Health. 2008 May;85(3):309-22
references.pmid: 18340537
references.citation: J Am Pharm Assoc (Wash). 2002 Nov-Dec;42(6 Suppl 2):S94-8
references.pmid: 12489625
references.citation: J Acquir Immune Defic Syndr. 2004 Oct 1;37(2):1307-12
references.pmid: 15385739
references.citation: Am J Public Health. 2007 Jan;97(1):117-24
references.pmid: 17138929
references.citation: J Urban Health. 2002 Dec;79(4):556-70
references.pmid: 12468675
references.citation: AIDS. 2000 Jun;14 Suppl 1:S57-62
references.pmid: 10981476